A phase II open label study of CB7630 (abiraterone acetate) in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Corticosteroids
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Cougar Biotechnology
- 10 Jun 2017 Biomarkers information updated
- 08 Aug 2012 Actual end date (1 Aug 2011) added as reported by ClinicalTrials.gov.
- 16 Feb 2011 Planned end date changed from 1 Dec 2007 to 1 Jun 2011 as reported by ClinicalTrials.gov.